The use of targeted, biologic (immunotherapy) & other forms of therapies administered to treat cancer through oncology drugs is known as cancer therapeutics. The global cancer therapeutics market size was valued at $98,900 million in 2018 and is estimated to reach at $180,193 million by 2026, registering a CAGR of 7.7% from 2019 to 2026.
Upsurge in collaboration between pharmaceutical companies, rise in cancer awareness & availability of oncology drugs, increase in cancer funding & research, and growth in geriatric population are the key factors that augment the growth of the cancer therapeutics market. Furthermore, rise in prevalence of cancer cases is expected to boost the market growth.
However, adverse effects associated with cancer therapeutics market and high costs associated with oncology drug development are some of the factors that impede the market growth. Conversely, the high potential of emerging economies and increase in demand for personalized medicine is expected to provide new opportunities for the market players in future.
The cancer therapeutics market is segmented based on application, top selling drugs, and region. Based on application, the market is divided into blood cancer, lung cancer, colorectal cancer, prostate cancer, breast cancer, cervical cancer, head & neck cancer, glioblastoma, malignant meningioma, mesothelioma, melanoma, and others. By top selling drugs, it is categorized into Revlimid, Avastin, Herceptin, Rituxan, Opdivo, Gleevec, Velcade, Imbruvica, Ibrance, Zytiga, Alimta, Xtandi, Tarceva, Perjeta, Temodar and others. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
KEY BENEFITS FOR STAKEHOLDERS
• This report entails a detailed quantitative market analysis from 2018 to 2026 to identify the prevailing opportunities along with strategic assessment of the global cancer therapeutics market.
• Cancer therapeutics market size and market estimations are based on a comprehensive analysis of the applications, top selling drugs, and developments in the industry.
• An in-depth analysis based on region assists to understand the regional market and facilitate the strategic business planning.
• The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the market.
KEY MARKET SEGMENTS
• By Application
o Blood Cancer
o Lung Cancer
o Colorectal Cancer
o Prostate Cancer
o Breast Cancer
o Cervical Cancer
o Head and Neck Cancer
o Glioblastoma
o Malignant Meningioma
o Mesothelioma
o Melanoma
o Others
• By Top Selling Drugs
o Revlimid
o Avastin
o Herceptin
o Rituxan
o Opdivo
o Gleevec
o Velcade
o Imbruvica
o Ibrance
o Zytiga
o Alimta
o Xtandi
o Tarceva
o Perjeta
o Temodar
o Others
• By Region
o North America
§ U.S.
§ Canada
o Europe
§ Germany
§ France
§ UK
§ Italy
§ Spain
§ Rest of Europe
o Asia-Pacific
§ Japan
§ China
§ India
§ Australia
§ South Korea
§ Taiwan
§ Rest of Asia-Pacific
o LAMEA
§ Latin America
§ Middle-East
§ Africa
The list of key players operating in this market include:
• F. Hoffmann-La Roche AG
• Bristol-Myers Squibb Company
• AbbVie, Inc.
• Johnson & Johnson
• Celgene Corporation
• Astellas Pharma, Inc.
• Pfizer, Inc.
• Novartis AG
• Merck KGaA
• Eli Lilly and Company
The other players included in the value chain analysis (and not included in the report) include:
• AstraZeneca plc
• Bayer AG
• Takeda Pharmaceutical Company Limited
CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.3.1. List of key players profiled in the report
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. KEY FINDINGS OF THE STUDY
2.2. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.2.2. Top winning strategies
3.3. Market share analysis, 2018
3.4. Porters five forces analysis
3.5. Clinical trials
3.6. Market dynamics
3.6.1. Drivers
3.6.1.1. Increase in prevalence of cancer
3.6.1.2. Surge in cancer research
3.6.1.3. Rise in strategic acquisitions & collaborations
3.6.2. Restraints
3.6.2.1. High cost of drug development and threat of failure
3.6.2.2. Adverse effects associated with cancer drug therapy
3.6.3. Opportunities
3.6.3.1. High potential associated with personalized medicines
3.6.3.2. Increase in purchasing power of emerging economies
CHAPTER 4: CANCER THERAPEUTICS MARKET, APPLICATION
4.1. Overview
4.1.1. Market size and forecast
4.2. Blood cancer
4.2.1. Key market trends, growth factors, and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market analysis, by country
4.3. Lung cancer
4.3.1. Key market trends, growth factors, and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market analysis, by country
4.4. Breast cancer
4.4.1. Key market trends, growth factors, and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market analysis, by country
4.5. Colorectal cancer
4.5.1. Key market trends, growth factors, and opportunities
4.5.2. Market size and forecast, by region
4.5.3. Market analysis, by country
4.6. Prostate cancer
4.6.1. Key market trends, growth factors, and opportunities
4.6.2. Market size and forecast, by region
4.6.3. Market analysis, by country
4.7. Cervical cancer
4.7.1. Key market trends, growth factors, and opportunities
4.7.2. Market size and forecast, by region
4.7.3. Market analysis, by country
4.8. Head & neck cancer
4.8.1. Key market trends, growth factors, and opportunities
4.8.2. Market size and forecast, by region
4.8.3. Market analysis, by country
4.9. Glioblastoma
4.9.1. Key market trends, growth factors, and opportunities
4.9.2. Market size and forecast, by region
4.9.3. Market analysis, by country
4.10. Malignant meningioma
4.10.1. Key market trends, growth factors, and opportunities
4.10.2. Market size and forecast, by region
4.10.3. Market analysis, by country
4.11. Mesothelioma
4.11.1. Key market trends, growth factors, and opportunities
4.11.2. Market size and forecast, by region
4.11.3. Market analysis, by country
4.12. Melanoma
4.12.1. Key market trends, growth factors, and opportunities
4.12.2. Market size and forecast, by region
4.12.3. Market analysis, by country
4.13. Others
4.13.1. Key market trends, growth factors, and opportunities
4.13.2. Market size and forecast, by region
4.13.3. Market analysis, by country
CHAPTER 5: CANCER THERAPEUTICS MARKET, BY TOP SELLING DRUGS
5.1. Overview
5.1.1. Market size and forecast
5.2. Revlimid
5.2.1. Market size and forecast, by region
5.2.2. Market analysis, by region
5.3. Avastin
5.3.1. Market size and forecast, by region
5.3.2. Market analysis, by region
5.4. Herceptin
5.4.1. Market size and forecast, by region
5.4.2. Market analysis, by region
5.5. Rituxan
5.5.1. Market size and forecast, by region
5.5.2. Market analysis, by region
5.6. Opdivo
5.6.1. Market size and forecast, by region
5.6.2. Market analysis, by region
5.7. Gleevec
5.7.1. Market size and forecast, by region
5.7.2. Market analysis, by region
5.8. Velcade
5.8.1. Market size and forecast, by region
5.8.2. Market analysis, by region
5.9. Imbruvica
5.9.1. Market size and forecast, by region
5.9.2. Market analysis, by region
5.10. Ibrance
5.10.1. Market size and forecast, by region
5.10.2. Market analysis, by region
5.11. Zytiga
5.11.1. Market size and forecast, by region
5.11.2. Market analysis, by region
5.12. Alimta
5.12.1. Market size and forecast, by region
5.12.2. Market analysis, by region
5.13. Xtandi
5.13.1. Market size and forecast, by region
5.13.2. Market analysis, by region
5.14. Tarceva
5.14.1. Market size and forecast, by region
5.14.2. Market analysis, by region
5.15. Perjeta
5.15.1. Market size and forecast, by region
5.15.2. Market analysis, by region
5.16. Temodar
5.16.1. Market size and forecast, by region
5.16.2. Market analysis, by region
5.17. Other drugs
5.17.1. Market size and forecast, by region
5.17.2. Market analysis, by region
CHAPTER 6: CANCER THERAPEUTICS MARKET, BY REGION
6.1. Overview
6.1.1. Market size and forecast
6.2. North America
6.2.1. Key market trends, growth factors, and opportunities
6.2.2. North America market size and forecast, by country
6.2.2.1. U.S.
6.2.2.1.1. U.S. market size and forecast, by application
6.2.2.2. Canada
6.2.2.2.1. Canada market size and forecast, by application
6.2.3. North America market size and forecast, by application
6.2.4. North America market size and forecast, by top selling drugs
6.3. Europe
6.3.1. Key market trends, growth factors, and opportunities
6.3.2. Europe cancer therapeutics market, by country
6.3.2.1. Germany
6.3.2.1.1. Germany market size and forecast, by application
6.3.2.2. France
6.3.2.2.1. France market size and forecast, by application
6.3.2.3. UK
6.3.2.3.1. UK market size and forecast, by application
6.3.2.4. Italy
6.3.2.4.1. Italy market size and forecast, by application
6.3.2.5. Spain
6.3.2.5.1. Spain market size and forecast, by application
6.3.2.6. Rest of Europe
6.3.2.6.1. Rest of Europe market size and forecast, by application
6.3.3. Europe market size and forecast, by application
6.3.4. Europe market size and forecast, by top selling drugs
6.4. Asia-Pacific
6.4.1. Key market trends, growth factors, and opportunities
6.4.2. Asia-Pacific market size and forecast, by country
6.4.2.1. Japan
6.4.2.1.1. Japan market size and forecast, by application
6.4.2.2. China
6.4.2.2.1. China market size and forecast, by application
6.4.2.3. India
6.4.2.3.1. India market size and forecast, by application
6.4.2.4. Taiwan
6.4.2.4.1. Taiwan market size and forecast, by application
6.4.2.5. South Korea
6.4.2.5.1. South Korea market size and forecast, by application
6.4.2.6. Australia
6.4.2.6.1. Australia market size and forecast, by application
6.4.2.7. Rest of Asia-Pacific
6.4.2.7.1. Rest of Asia-Pacific market size and forecast, by application
6.4.3. Asia-Pacific market size and forecast, by application
6.4.4. Asia-Pacific market size and forecast, by top selling drugs
6.5. LAMEA
6.5.1. Key market trends, growth factors, and opportunities
6.5.2. LAMEA market size and forecast, by country
6.5.2.1. Latin America
6.5.2.1.1. Latin America market size and forecast, by application
6.5.2.2. Middle East
6.5.2.2.1. Middle East market size and forecast, by application
6.5.2.3. Africa
6.5.2.3.1. Africa market size and forecast, by application
6.5.3. LAMEA market size and forecast, by application
6.5.4. LAMEA market size and forecast, by top selling drugs
CHAPTER 7: COMPANY PROFILES
7.1. AbbVie Inc.
7.1.1. Company overview
7.1.2. Company snapshot
7.1.3. Operating business segments
7.1.4. Product portfolio
7.1.5. Business performance
7.1.6. Key strategic moves and developments
7.2. Astellas Pharma Inc.
7.2.1. Company overview
7.2.2. Company snapshot
7.2.3. Operating business segments
7.2.4. Product portfolio
7.2.5. Business performance
7.2.6. Key strategic moves and developments
7.3. Bristol Myers Squibb Company
7.3.1. Company overview
7.3.2. Company snapshot
7.3.3. Operating business segments
7.3.4. Product portfolio
7.3.5. Business performance
7.3.6. Key strategic moves and developments
7.4. Celgene Corporation
7.4.1. Company overview
7.4.2. Company snapshot
7.4.3. Operating business segments
7.4.4. Product portfolio
7.4.5. Business performance
7.4.6. Key strategic moves and developments
7.5. Eli Lilly and Company
7.5.1. Company overview
7.5.2. Company snapshot
7.5.3. Operating business segments
7.5.4. Product portfolio
7.5.5. Business performance
7.5.6. Key strategic moves and developments
7.6. F. Hoffmann-La Roche Ltd.
7.6.1. Company overview
7.6.2. Company snapshot
7.6.3. Operating business segments
7.6.4. Product portfolio
7.6.5. EleInformatiBusiness performance
7.6.6. Key strategic moves and developments
7.7. Johnson & Johnson
7.7.1. Company overview
7.7.2. Company snapshot
7.7.3. Operating business segments
7.7.4. Product portfolio
7.7.5. Business performance
7.7.6. Key strategic moves and developments
7.8. Merck & Co., Inc.
7.8.1. Company overview
7.8.2. Company snapshot
7.8.3. Operating business segments
7.8.4. Product portfolio
7.8.5. Business performance
7.8.6. Key strategic moves and developments
7.9. Novartis AG
7.9.1. Company overview
7.9.2. Company snapshot
7.9.3. Operating business segments
7.9.4. Product portfolio
7.9.5. Business performance
7.9.6. Key strategic moves and developments
7.10. Pfizer Inc.
7.10.1. Company overview
7.10.2. Company snapshot
7.10.3. Operating business segments
7.10.4. Product portfolio
7.10.5. Business performance
7.10.6. Key strategic moves and developments
Trends Market Research © Copyright 2020. All Rights Reserved.
